Ctim-27. Doc1021 Cell-Based Vaccination As Adjuvant Therapy For Glioblastoma: Phase I Clinical Trial Analysis
Yoshua Esquenazi,Jay Zhu,Sigmund Hsu,Rodrick Zvavanjanja,Mia Vu,Eva Highberg,Trivedi Akshar,Wei Liu,Madhuri Namekar,Colby Hofferek,James Ernste,Corey Mossop,Clay Christina,Sabina Amin,Musher Benjamin,Vinod Ravi,Kemnade Jan,Laura Aguilar,Alan Turtz,Nitin Tandon,Vanaja Konduri,Joseph Georges,William Decker
DOI: https://doi.org/10.1093/neuonc/noae165.0360
2024-11-29
Neuro-Oncology
Abstract:Glioblastoma is an aggressive tumor for which median survival remains 14-18 months despite aggressive standard of care. Cellular immunotherapy approaches have recently shown promise. Homologous antigenic loading is an ex-vivo technique that leverages p38MAPK and mTORC1 signaling cascades to initiate powerful cDC1-like skewing in monocyte-derived dendritic cells, leading to downstream induction of tissue-infiltrating, cytolytic effector memory T-cells. This open-label phase I clinical trial evaluated the autologous dendritic cell vaccine DOC1021 prepared through homologous antigenic loading and administered bilaterally near the deep cervical lymph nodes. Three courses of vaccine were administered every 2 weeks after completion of chemoradiation, adjuvanted concurrently with six weeks of weekly type I interferon. Four dose levels from 3.5x10 6 to 3.6x10 7 total vaccine cells were tested. Tumor progression prior to vaccination was not an exclusion criterion. Sixteen newly diagnosed IDH-WT patients completed treatment, median age 63 years and 94% MGMTp unmethylated. The most common related AEs were grade 1 injection-site reactions and grade 1-3 fatigue and urticaria. No DLTs were observed. Immunohistochemistry of tumors derived from early post-vaccination second resections showed enhanced CD8 + T-cell infiltration and pathologic findings consistent with residual rather than relapsed GBM in 2/3 patients. Analysis of post-vaccination PBMC in dose level cohorts 2-4 indicated expansion of both CD4 + (13/13) and CD8 + (11/13) central memory T-cell compartments (p<0.002 and p<0.05, respectively) as well as expansion of CD8 + CD127 + T-cells (12/13; p<0.001). Among three patients for whom tissue was obtained pre- and post-vaccination, clinical outcomes correlated with Visium spatial transcriptomic analysis. Median survival for the MGMTp unmethylated cohort (n=15) has not yet been reached but is statistically greater (p<0.05) than that of matched historic controls. The results indicate that DOC1021 is safe, can be effectively integrated within existing standards of care and is potentially efficacious in a challenging patient population.
oncology,clinical neurology